Child-Pugh Stage Predicts Survival in Hospitalized Patients with Decompensated Cirrhosis: A 10-Year Cohort Study

Ion Dina1,2, Claudia Georgeta Iacobescu2, Ioana Valeria Grigorescu2

  • 1Clinical Department 1-Medical Semiology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Insights

The Child-Pugh score effectively predicts survival in hospitalized patients with decompensated cirrhosis, with Child-Pugh C indicating significantly higher mortality risk. This classification remains crucial for early risk stratification in emergency settings.

Area of Science:

  • Hepatology
  • Clinical Prognostics
  • Epidemiology

Background:

  • Decompensated liver cirrhosis presents high short-term mortality in hospitalized patients.
  • The Child-Pugh classification's prognostic value needs evaluation in tertiary emergency settings.
  • This study assesses Child-Pugh stage and clinical factors' impact on survival.

Purpose of the Study:

  • To evaluate the prognostic role of Child-Pugh stage in hospitalized cirrhotic patients.
  • To identify independent predictors of short- and mid-term mortality.
  • To assess survival over a 10-year period in a real-world tertiary emergency setting.

Main Methods:

  • Retrospective cohort study of 2831 hospitalized cirrhotic patients (2015-2025).
  • Survival analysis included 631 patients with complete Child-Pugh staging.
  • Kaplan-Meier curves, log-rank tests, and Cox/logistic regression models were used.

Main Results:

  • In-hospital mortality increased significantly with Child-Pugh stage (A: 1.2%, B: 9.0%, C: 46.7%).
  • One-year survival rates were 98.7% (A), 83.6% (B), and 40.7% (C).
  • Mixed cirrhosis type (HR=8.58) and Child-Pugh C (HR=25.11) were strongest mortality predictors; ascites showed inverse association (OR=0.62).

Conclusions:

  • Child-Pugh stage is a robust independent predictor of survival in decompensated cirrhosis.
  • The significant survival gradient across stages underscores its clinical utility.
  • Early risk stratification using Child-Pugh staging is vital in tertiary emergency care.

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...